Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial Results.

Women's health (London, England)·2026
Same author

Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same author

Nocturia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same author

A Contemporary View of Menopausal Hormone Therapy: Correction.

Obstetrics and gynecology·2026
Same author

Quantification of "Mercy Sex" in Heterosexual Women.

Journal of sex & marital therapy·2026
Same author

Report of the FDA's expert panel on hormone therapy.

Menopause (New York, N.Y.)·2026

Related Experiment Video

Updated: Jun 15, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Are all bisphosphonates the same? Potential reasons for clinical differences: a perspective.

James A Simon1

  • 1Department of Obstetrics and Gynecology, George Washington University, School of Medicine, Washington, District of Columbia, USA. jsimon@jamesasimonmd.com

Journal of Women'S Health (2002)
|March 6, 2010
PubMed
Summary

Bisphosphonates vary in fracture protection scope and speed. Understanding these differences, particularly in the R2 side chain, is crucial for selecting the optimal osteoporosis treatment for individual patients.

Related Experiment Videos

Last Updated: Jun 15, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Area of Science:

  • Pharmacology
  • Osteoporosis Treatment
  • Bone Biology

Background:

  • Bisphosphonates are primary treatments for postmenopausal osteoporosis.
  • Practitioners often perceive bisphosphonates as interchangeable.
  • Emerging research indicates significant differences in their effectiveness and safety.

Purpose of the Study:

  • To highlight the meaningful clinical differences between various bisphosphonates.
  • To explain how structural variations influence bisphosphonate outcomes.
  • To inform physicians on optimal bisphosphonate selection for individual patients.

Main Methods:

  • Analysis of data from randomized controlled trials.
  • Review of observational database studies.
  • Examination of bisphosphonate chemical structures and mechanisms of action.

Main Results:

  • Bisphosphonates demonstrate variability in vertebral and nonvertebral fracture protection.
  • Differences exist in the speed of onset for antifracture effects.
  • The R2 side chain's structure, including nitrogen presence and orientation, impacts potency.

Conclusions:

  • Structural differences, specifically in the R2 side chain, account for observed clinical outcome variations.
  • Physicians must be aware of these distinctions for personalized osteoporosis management.
  • Optimizing bisphosphonate therapy requires understanding individual drug properties.